{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:59:35Z","timestamp":1785394775843,"version":"3.55.0"},"reference-count":50,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>With the range of options available for the treatment of Crohn\u2019s disease, therapy selection can be challenging in clinical practice. Comparative efficacy data are needed to clarify the relative position of the increasingly complex portfolio of advanced therapies and guide decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Our aim was to compare all advanced and immunomodulator treatments for efficacy and safety in maintenance of remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review and network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>We searched databases up to June 2025. Our outcomes were clinical relapse, loss of response, endoscopic relapse, and safety outcomes. We estimated risk ratio (RR) and 95% confidence interval (CI). We used GRADE to assess certainty of results, and surface under the cumulative ranking curve for ranking treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 37 randomised controlled trials with 7415 participants were included. Interventions ranged between 22\u2009weeks and 2\u2009years. Adalimumab probably prevents clinical relapse over placebo (RR 0.68, 95% CI 0.54\u20130.84, Number Needed to Treat (NNT)\u2009=\u20092, moderate effect magnitude). CT-P13 (RR 0.52, 95% CI 0.38\u20130.71) and infliximab (RR 0.61, 95% CI 0.49\u20130.76) may prevent clinical relapse. Upadacitinib is more effective than placebo at preventing loss of clinical response (RR 0.64, 95% CI 0.57\u20130.72, NNT\u2009=\u20092, small magnitude), while CT-P13 (RR 0.46, 95% CI 0.35\u20130.53, NNT\u2009=\u20091, large magnitude), natalizumab (RR 0.54, 95% CI 0.43\u20130.68, NNT\u2009=\u20092, moderate magnitude), certolizumab (RR 0.57, 95% CI 0.47\u20130.7), NNT\u2009=\u20092, moderate magnitude), adalimumab (RR 0.68, 95% CI 0.61\u20130.75, NNT\u2009=\u20092, small effect magnitude) and ustekinumab (RR 0.73, 95% CI 0.61\u20130.86, NNT\u2009=\u20092, small magnitude) probably prevent loss of clinical response. Infliximab (RR 0.7, 95% CI 0.59\u20130.82) and vedolizumab (RR 0.82, 95% CI 0.68\u20130.99) may prevent loss of clinical response. Endoscopic relapse could not be analysed. Safety evidence is uncertain, but treatments appear generally safe in the short term.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Adalimumab has moderate certainty for maintaining clinical remission with a moderate effect size. Novel therapies seem to have similar effect sizes, though imprecision due to limited evidence precludes further conclusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/knowledge.lancashire.ac.uk\/id\/eprint\/53237\/\">https:\/\/knowledge.lancashire.ac.uk\/id\/eprint\/53237\/<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261470683","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:24:22Z","timestamp":1785147862000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunomodulators and advanced therapies for maintenance of remission in Crohn\u2019s disease: systematic review and network meta-analysis"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2831-9406","authenticated-orcid":false,"given":"Vassiliki","family":"Sinopoulou","sequence":"first","affiliation":[{"name":"School of Medicine, University of Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-5158","authenticated-orcid":false,"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Lancashire, Harrington Building HA340, Preston PR1 2HE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Arruda Navarro Albuquerque","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aderonke","family":"Ajiboye","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheer Kumar","family":"Vuyyuru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine &amp; Health Sciences, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0810","authenticated-orcid":false,"given":"Shellie Jane","family":"Radford","sequence":"additional","affiliation":[{"name":"Faculty of Medicine &amp; Health Sciences, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon William","family":"Moran","sequence":"additional","affiliation":[{"name":"Faculty of Medicine &amp; Health Sciences, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2023-0493"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036584"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221078456"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00688-2"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0050"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01762-8"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2023-102559"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328052"},{"key":"e_1_3_4_11_2","article-title":"Network meta-analysis to evaluate the comparative efficacy of biologics for maintenance treatment of adult patients with Crohn\u2019s disease","volume":"166","author":"Schreiber S","year":"2024","unstructured":"Schreiber S, Danese S, Colombel J-F, et al. Network meta-analysis to evaluate the comparative efficacy of biologics for maintenance treatment of adult patients with Crohn\u2019s disease. Gastroenterology 2024; 166: S10.","journal-title":"Gastroenterology"},{"key":"e_1_3_4_12_2","unstructured":"Gordon M Sinopoulou V Moran G et al. Efficacy and safety of therapies for induction and maintenance of remission in Crohn\u2019s disease: protocol for a network meta-analysis. University of Central Lancashire: CLoK 2024. https:\/\/clok.uclan.ac.uk\/53237"},{"key":"e_1_3_4_13_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf191"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(24)01957-7"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2022-001067"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf085"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3542"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"e_1_3_4_21_2","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2021","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2021."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v106.i02"},{"key":"e_1_3_4_23_2","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework","volume":"371","author":"Brignardello-Petersen RA-O","year":"2020","unstructured":"Brignardello-Petersen RA-O, Florez ID, Izcovich A, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020; 371: m3907.","journal-title":"BMJ"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad047"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"e_1_3_4_26_2","first-page":"229","article-title":"Efficacy of infliximab combined with azathioprine for moderate to severe Crohn\u2019s disease","volume":"18","author":"Duan Z","year":"2013","unstructured":"Duan Z, Luo J, Li W. Efficacy of infliximab combined with azathioprine for moderate to severe Crohn\u2019s disease. Chin J Gastroenterol 2013; 18: 229\u2013232.","journal-title":"Chin J Gastroenterol"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00252-1"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.01.047"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.008"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32196-2"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.024"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw152"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60304-9"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200061"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00385-5"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_3_4_38_2","article-title":"SIMILAR trial\u2014efficacy of infliximab-biosimilar compared to infliximab-biological in patients with inflammatory bowel disease in remission\u2014a randomized, controlled, double blind, phase 4 noninferiority trial","volume":"5","author":"Volkers A","year":"2017","unstructured":"Volkers A, Jansen J. SIMILAR trial\u2014efficacy of infliximab-biosimilar compared to infliximab-biological in patients with inflammatory bowel disease in remission\u2014a randomized, controlled, double blind, phase 4 noninferiority trial. United Eur Gastroenterol J 2017; 5: A307.","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.05.006"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.01.035"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00303-X"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30012-3"},{"key":"e_1_3_4_45_2","article-title":"Methotrexate for maintenance of remission in Crohn\u2019s disease","volume":"2014","author":"Patel V","year":"2014","unstructured":"Patel V, Wang Y, MacDonald JK, et al. Methotrexate for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2014; 2014: CD006884.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00312-5"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00233-4"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-023-04378-w"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261470683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261470683","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261470683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:17:59Z","timestamp":1785392279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261470683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["10.1177\/17562848261470683"],"URL":"https:\/\/doi.org\/10.1177\/17562848261470683","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17562848261470683"}}